Corrigendum

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”

S. P. D’Angelo,1,2 W. D. Tap,1,2 G. K. Schwartz,1,2 and R. D. Carvajal1,2

1Department of Medicine/Melanoma-Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
2Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA

Correspondence should be addressed to S. P. D’Angelo; dangelos@mskcc.org

Received 21 May 2015; Accepted 27 May 2015

Copyright © 2015 S. P. D’Angelo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the paper titled “Sarcoma Immunotherapy: Past Approaches and Future Directions” in the following sentence: “Currently, there is a phase II trial of a trivalent peptide vaccine to the gangliosides GD2, GD3, and GM2 in patients with sarcoma that have had solitary metastases excised (NCT00597272),” the corrected identifier should be NCT01141491.